Disparities in subgroup populations enrolled in lung cancer trials

Antonio Rossi, Giovanni Palazzolo, Domenico Galetta

Research output: Contribution to journalArticlepeer-review


Lung cancer is the leading cause of cancer-related mortality worldwide. All drugs available for the treatment of lung cancer reached the market after reporting positive results from pivotal clinical studies. However, in these trials not all patient subgroups are adequately represented, with some discrepancies reported in patients' accrual especially concerning age, gender and ethnicity. Hence, a new drug entering the market for the treatment of all patients may have been investigated only in certain patient subgroups, while the reported results have been generalized for the therapy of all patients. The impact of certain characteristics such as gender, ethnicity and age of patients enrolled in randomized trials on the final results has been examined and discussed in this article.

Original languageEnglish
Pages (from-to)163-172
Number of pages10
JournalExpert Review of Respiratory Medicine
Issue number2
Publication statusPublished - Apr 2012


  • discrepancies
  • drug development
  • lung cancer
  • minorities
  • non-small-cell lung cancer
  • randomized trials
  • small-cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Disparities in subgroup populations enrolled in lung cancer trials'. Together they form a unique fingerprint.

Cite this